StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.90+0.21 (+1.96%)

Close on Nov 18, 2026Market cap $537.45MP/E –Yield –

ArriVent BioPharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ArriVent BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$175.94M. For fiscal 2025 it was -$177.53M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$177.53M–
FY2024Dec 31, 2024-$94.31M–
FY2023Dec 31, 2023-$74.59M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$52.69M–
Q1 FY2026Mar 31, 2026-$46.11M–
Q4 FY2025Dec 31, 2025-$38.82M–
Q3 FY2025Sep 30, 2025-$38.32M–
Q2 FY2025Jun 30, 2025-$33.62M–
Q1 FY2025Mar 31, 2025-$66.77M–
Q4 FY2024Dec 31, 2024-$23.71M–
Q3 FY2024Sep 30, 2024-$24.23M–
Q2 FY2024Jun 30, 2024-$25.70M–
Q1 FY2024Mar 31, 2024-$20.67M–
Q4 FY2023Dec 31, 2023-$23.12M–
Q3 FY2023Sep 30, 2023-$16.72M–
Q2 FY2023Jun 30, 2023-$22.58M–
Q1 FY2023Mar 31, 2023-$12.17M–

More ArriVent BioPharma figures

See a number that looks wrong?